Genovis’ Board of Directors has decided upon a private placement

Following authorization by the Extraordinary General Meeting of November 19, 2013, Genovis’ Board of Directors has decided upon a private placement of a maximum of 804,643 shares in the company. The subscription period runs until January 20 and the subscription price is SEK 4.50, which is the same as in the rights issue with the subscription period December 2 to 16, 2013.The issue will raise a maximum of SEK 3.6 million for the company and share capital could increase by a maximum of SEK 321,857.20. Following the completed private placement, share capital will amount to a maximum of SEK 8,738,260.80 and the number of shares will be a maximum of 21,845,652. The reason for deviation from shareholders’ preferential rights is to be able to take advantage of interest from underwriters within the framework of issued underwriting guarantees in the rights issue with the subscription period December 2-16, 2013.

The issue will have a dilutive effect of about 3%.

For more information, please contact: Sarah Fredriksson, CEO, Genovis AB Tel: 46 (0)46 -101235 sarah.fredriksson@genovis.com

ABOUT GENOVIS

Genovis’ business concept is to develop, produce and market innovative technologies that facilitate and enable development of new treatment methods and diagnostics for customers in the medical device and pharmaceutical industries. The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis develops and sells unique enzymes (protein engineering portfolio) in innovative product formats that facilitate development and quality control of and biological drugs. GeccoDots uses nanotechnology to produce a new type of contrast agent that is used in medical imaging.

Genovis shares are listed on NASDAQ OMX First North, and Thenberg Fondkommission is Certified Adviser for the Company, t: 46 (0)31-745 50 00